



IN COLLABORATION WITH INSIGHTS  
PARTNER MCKINSEY & COMPANY

SEPT  
9-11  
2024

NASHVILLE, TENNESSEE  
Four Seasons  
Hotel Nashville

[BIOCENTURYGRANDROUNDS.COM](https://BIOCENTURYGRANDROUNDS.COM)

#### Organized by

**BIOCENTURY**

#### Insights Partner

McKinsey  
& Company

#### Founding Investors



F2 Ventures




Sofinnova  
partners



# Join BioCentury's Signature R&D Conference

BioCentury Grand Rounds is a new interdisciplinary forum of top academic and biopharma R&D leaders to showcase groundbreaking research, clinical insights, and transformative technologies with significant commercial potential.



**At BioCentury Grand Rounds, discover the next wave of biotech breakthroughs and the people driving them. Be part of the dialogue solving today's problems in translation to enable tomorrow's medicines.**

## Who you will meet:

Academic  
Translational  
Researchers

Biopharma  
R&D Leaders

Thought  
Leaders: From  
Today and  
Tomorrow

Early Stage  
Investors

Founders,  
CEOs

## The conference will:

- Introduce VCs and pharmas to emerging academic innovators and physician scientists — from all regions — working on early-stage science with commercial potential
- Gather innovators and entrepreneurs to present leading edge discoveries, via presentations and poster sessions
- Engage thought leaders to discuss critical challenges at the interface of academia and industry



# What to Expect



## Debate R&D Strategy

Discuss critical bottlenecks in translation of breakthrough science to successful drug development programs



## Discover Groundbreaking Research

40+ Presenting Companies and 50+ Translational Posters — selected by BioCentury



## Schedule Meetings

Partner with investors, biopharma leaders, emerging academic innovators



## Network with Peers

Build connections with decision-makers in an intimate setting



## Take Home the Conference Report

Insights Partner McKinsey & Company looks at challenges that must be solved to translate breakthrough innovations

## Why Attend?

### A unique convergence of minds

Grand Rounds is not just another industry conference; it's a vital intersection of academia, industry, and investment within the biopharma sphere. This event is specifically designed to foster collaboration and networking among academic innovators, R&D leaders, venture capitalists, and biotech executives, facilitating discussions at the crucial academia/industry interface to drive innovation.

### Focus on forward-thinking innovation

The conference is deeply invested in unveiling the future of biopharma, spotlighting emerging science and technology that promises to revolutionize patient care. It stands out by dedicating itself to the exploration of mechanistic biology and the translation of high-potential academic discoveries into tangible drug development opportunities, highlighting new best practices from AI to pharmacology.

### Strategic industry dialogues and deep dives

Beyond general networking, Grand Rounds offers a platform for critical industry dialogues that address and aim to overcome the bottlenecks in translating academic discoveries to commercial successes. Discussions are not just theoretical but are geared towards actionable solutions that can accelerate drug development.

### Catalyst for groundbreaking collaborations

Grand Rounds is the catalyst for future biotech innovation, bridging gaps between early-stage research and its commercialization. It's an event where the next big breakthroughs in biotech R&D are not just discussed but actively shaped through collaborations that span continents and disciplines, offering unparalleled access to a curated, high-caliber network of industry changemakers.

### An experience beyond the conference room

Set in Nashville, the conference promises not just insightful panels and sessions but an immersive networking experience that leverages the city's rich cultural and innovative ecosystem. This "destination experience" is crafted to strengthen professional relationships in a vibrant, memorable setting.

# Steering Committee



Amy Abernethy, M.D., Ph.D.  
Former Principal Deputy  
Commissioner  
FDA



Chris Arendt, Ph.D.  
CSO, Head of Research  
Takeda



Jamil Beg  
Partner  
SV Health Investors



Luciana Borio, M.D.  
Venture Partner  
Arch Venture Partners



Shelley Chu, M.D., Ph.D.  
Partner, Head of Biotech  
Lightspeed Ventures



Mark Currie, Ph.D.  
Venture Partner  
Iaso Ventures



Simone Fishburn, Ph.D.  
VP & Editor in Chief  
BioCentury Inc.



Todd Foley  
Managing Director  
MPM BioImpact



Kathleen Giacomini, Ph.D.  
Dean, School of Pharmacy  
UCSF



David Goldstein, Ph.D.  
Co-founder & CEO  
Actio Biosciences



Jane Grogan, Ph.D.  
EVP, Head of Research  
Biogen



Colin Hill  
CEO  
Aitia



Najat Khan, Ph.D.  
Chief Data Science Officer  
Recursion Pharmaceuticals



Sophie Kornowski, Pharm.D.  
CEO  
Boston Pharmaceuticals



Olivier Leclerc  
Senior Partner  
McKinsey & Company



John Lepore, M.D.  
CEO  
ProFound Therapeutics



Mathai Mammen, M.D., Ph.D.  
Chairman & CEO  
FogPharma



Fiona Marshall, Ph.D.  
President of Biomedical  
Research  
Novartis



Antoine Papiernik  
Chairman & Managing  
Partner  
Sofinnova Partners



Kush Parmar, M.D., Ph.D.  
Managing Partner  
SAM Ventures



Cary Pfeffer, M.D.  
Partner  
Third Rock Ventures



Robert Plenge, M.D., Ph.D.  
EVP, Chief Research Officer  
Bristol Myers Squibb



Daniel Reich, M.D., Ph.D.  
Chief, Translational  
Neuroradiology Section,  
NINDS, NIH Attending  
Neuroradiologist, NIH Clinical  
Center



Klaus Romero, M.D.  
CEO  
Critical Path Institute



Paul Peter Tak, M.D., Ph.D.  
President & CEO  
Candel Therapeutics



Nikhil Wagle, M.D.  
VP & Global Head of  
Translational Medicine  
Genentech



Douglas Williams, Ph.D.  
Chairman  
AC Immune

# Presenting Companies

TUESDAY, SEPTEMBER 10, 2024	
SALON A	
TECHBIO AND AI-GUIDED DRUG DEVELOPMENT	
10:20 AM	BioCorteX Ltd.
NEUROLOGY	
10:30 AM	Basking Biosciences Inc.
10:40 AM	Epiodyne Inc.
CELL AND GENE THERAPY	
10:50 AM	EG 427 S.A.S.
11:00 AM	EpiCure Therapeutics Inc.
11:10 AM	Mahzi Therapeutics Inc.
11:20 AM	Stand Up Therapeutics Co. Ltd.
11:30 AM	Spur Therapeutics Ltd.
11:40 AM	Anocca AB
11:50 AM	Dynamic Cell Therapies Inc.
HOT TOPICS	
12:00 PM	Radar Therapeutics Inc.
12:10 PM	Lynch Regenerative Medicine LLC
12:20 PM	Boston Pharmaceuticals Inc.
AUTOIMMUNE, INFLAMMATION AND FIBROSIS	
1:30 PM	2A Biosciences Inc.
1:40 PM	MirimGENE Co. Ltd.
1:50 PM	Olatec Therapeutics LLC
2:00 PM	Senelix Co. Ltd
2:10 PM	Azcuris Co. Ltd.
CANCER	
2:20 PM	Abion Inc.
2:30 PM	Candel Therapeutics Inc.
2:40 PM	Ascensus Therapeutics Inc.
2:50 PM	Reglagene LLC
3:00 PM	RheADC
3:10 PM	TFC Therapeutics Inc.
3:20 PM	InnoCure Therapeutics Inc.
3:30 PM	Tolremo Therapeutics AG
TECHBIO AND AI-GUIDED DRUG DEVELOPMENT	
3:40 PM	Safenía Therapeutics Inc.
3:50 PM	VRG Therapeutics plc
4:00 PM	Novomab
4:10 PM	Duet BioSystems Inc.
4:20 PM	Linus Biotechnology Inc.
HOT TOPICS	
4:30 PM	Peroxitech Inc.
4:40 PM	Pi Health Inc.
4:50 PM	Virometix AG
5:00 PM	Eupalinos Inc.
5:10 PM	Hope Medicine Inc.





# Preliminary Agenda

## Monday, September 9, 2024

- 11:00 am – 3:00 pm **Pre-Event Networking Excursion & Lunch**  
Join us for a visit to the National Museum of African American Music, including a delightful lunch. Get the networking started early while immersing yourself in one of the jewels of Nashville, the only museum dedicated to the history of Black music, integrating history and interactive technology to bring musical heroes of the past to the present. Discover the stories behind the rhythms and melodies that have shaped genres from jazz and blues to hip-hop and R&B.  
*\*Limited Capacity, additional registration required. Email: [conferences@biocentury.com](mailto:conferences@biocentury.com) for more information.*
- 4:00 pm – 4:30 pm General Registration & Networking
- 4:30 pm – 5:30 pm **Opening Plenary & Fireside Chat: Bending the Curve on Translational Research**  
From causal biology to targeted delivery, R&D leaders are changing both the conversation and the tools of drug discovery. The goal is to fundamentally alter the probability of success in translating from discovery to the clinic. In this fireside chat, the Heads of Research at Novartis and Biogen discuss their approach to preclinical research and translation, and how they are bridging the link with academia to capitalize on the newest discoveries.  
Chair: Simone Fishburn, VP & Editor in Chief, BioCentury  
Panelist: Fiona Marshall, Ph.D., President of Biomedical Research, Novartis
- 5:30 pm – 7:00 pm Networking Welcome Reception

## Tuesday, September 10, 2024


- 7:30 am – 8:45 am **General Registration & Networking Breakfast**
- 8:00 am – 8:45 am **Breakfast Workshop: Getting Corporate Formation Right**  
Getting the science to work is arguably not the hardest part of being a scientific founder. Creating a company can be even more of a challenge, from protecting IP to raising money. What do scientific founders and executives need to understand prior to forming a life science company? How do you build a company from Day 1 that is attractive to future partners and investors? What are common pitfalls that trip up first-time CEOs?  
*This interactive workshop brings together academics, lawyers, investors, and dealmakers to discuss how to get company formation right.*  
Chair: Eric Pierce, Executive Director, Corporate Alliances, BioCentury  
Panelists: Jory Bell, General Partner, Playground Global  
Chris Garabedian, Venture Portfolio Manager, Perceptive Advisors and CEO, Xontogeny  
Guru Laxmikanthan, Ph.D., Patent Attorney, Nutter  
Art Pappas, Managing Partner, Pappas Capital  
Jim Ray, Ph.D., Executive Director, Neurodegenerative Consortium, MD Anderson Cancer Center
- 8:00 am – 5:30 pm C-level Partnering Meetings
- 8:45 am – 9:00 am Official Welcome from BioCentury

9:00 am – 10:00 am

### Conference Report: Reimagining translation: how to unlock the next wave of breakthrough treatments

Biotechnology breakthroughs rely on efficient and effective mechanisms to advance high-potential translational research. At a moment of accelerated biopharma innovation, there is an opportunity for industry, academia and other stakeholders to collaborate in new ways to help unlock the next wave of breakthrough therapies. Insights Partner McKinsey & Company examines the current state of biopharma research and forecasts where translation is headed in the 2024 Grand Rounds Conference Report. Advanced access to McKinsey's report will be available exclusively to all Grand Rounds delegates.

Co-chairs: Peter Wright, Ph.D., Partner, McKinsey & Company  
Guang Yang, Ph.D., Partner, McKinsey & Company



## GRAND ROUNDS I: TRANSLATIONAL BOTTLENECKS

### Uncorking innovation: Critical issues hampering the acceleration of translation

Against the backdrop of escalating discoveries and breakthroughs over the past decade, critical bottlenecks are holding back their conversion to value-driving drug development. Inefficiencies in translation extend from poor disease models to underdeveloped delivery technology to mismatched expectations for what constitutes validation. The Bottleneck Rounds will unpack the strategies for overcoming these roadblocks.

10:00 am – 10:40 am

### From causal biology to preclinical validation: What makes the grade in 2024?

Scientist-entrepreneurs hope to win attention and money from investors and pharmas, but often run afoul of what evidence constitutes preclinical validation. Drug developers are making clear that causal biology is the North Star, however reaching it is not straightforward. The issue spans the target's origin, model systems, experimental design, statistical robustness and effect size that will convince the buy-side a signal is a meaningful result. This Round will discuss what investors and pharmas want to see, and how ambitious scientists can strengthen the case for translating their research projects from academia to industry.

Chair: John Lepore, M.D., CEO, ProFound Therapeutics

Panelist: Chris Hollowood, Ph.D., CEO Syncona  
Carrie Jones, Ph.D., Associate Professor of Pharmacology, Vanderbilt University  
Chaitan Khosla, Ph.D., Professor of Chemistry, Stanford University  
John Kuriyan, Ph.D., Dean of Basic Sciences and Professor of Biochemistry,  
Vanderbilt University School of Medicine  
Nikhil Wagle, M.D., VP & Global Head of Translational Medicine, Genentech




10:20 am – 5:30 pm

Presenting Companies

10:40 am – 11:10 am

Morning Networking Break

11:10 am – 11:50 am



### The human first era is here: Is there still value in new animal models?

Animal models arguably have done what they can for translation. They'll likely persist for PK and tox studies. For functional readouts in disease, however, use of animal models is driven by inertia, routine, regulatory requirements and lack of other options, rather than their predictive potential. With investors and pharmas increasingly seeing human data as ground zero for drug development, where should researchers be focused on building model systems? This Round will discuss what animal models are proving their worth, where transformational new ones might emerge, and what alternative systems, such as patient-derived iPSCs and organoids, are yielding proof of concept that investors, pharmas and regulators will accept.

Chair: Anika Gupta, Ph.D., Principal, GV


Panelists: Manuel Ascano, Ph.D., Associate Professor of Biochemistry, Vanderbilt University School of Medicine

Lori Aschenbrenner, Ph.D., Director, Drug Development and Regulatory Strategy, Early Phase Development Solutions, Labcorp

Andrei Georgescu, Ph.D., Co-founder & CEO, Vivodyne

Patrick Lyden, M.D., Professor, Keck School of Medicine of USC

11:50 am – 12:30 pm



### Delivery on demand: Still the elephant in the room

The rush of new modalities has not been matched by advances in highly targeted delivery, particularly for nucleic acid therapies. Enabling DNA- and RNA-based therapies to reach any cell in the body, on demand, would open untold target space and therapeutic opportunities. Beyond viral vectors, a slow wave in nonviral technologies is building. This Round will evaluate which approaches to tissue-specific delivery promise greater success and consider whether precompetitive approaches or delivery-focused service models will benefit both academic researchers and drug developers.

Chair: Douglas Williams, Ph.D., Chairman, AC Immune

Panelist: Melissa Bonner, Ph.D., Chief Scientific Officer, Nvelop Therapeutics  
Kevin Friedman, Ph.D., Co-founder & CEO, Kelonia Therapeutics  
Matthew Wilson, M.D., Ph.D., Professor of Medicine, Vanderbilt University Medical Center

Carolyn Zimmermann, Chief Business Officer, SonoThera

12:30 pm – 1:30 pm

Networking Lunch



## GRAND ROUNDS II: THE MODALITY GROUNDBREAKERS

### A mountain of modalities: Now comes the translational loop

Academic innovators have powered most of the groundbreaking technologies that have yielded mountains of new modalities from CRISPR to gene therapies to CAR T to mRNA. The handoff to industry is allowing such discoveries to reach patients, but some of these transformations must overcome limitations that cap their use. For these, the translational loop puts the creation of next-generation iterations back in the hands of researchers. The Modality Groundbreaker Rounds will identify these potential solutions, and address how drug developers can prioritize among the innovations in a modality to bring treatments to patients most efficiently.



1:30 pm – 2:10 pm



### **The heyday of AAV engineering is here: Will it deliver?**

AAVs have all but crowded out other viruses as the gene therapy vector of choice, and now promise to go beyond genetic diseases via the creation of vectorized antibodies and proteins that could compete with traditional biologics. Engineering advances with capsid optimization, inducible expression technologies and packaging are solving for toxicities, limits on targeting precision, cargo size, scalability and other manufacturing hurdles. This Round will evaluate the most efficient ways for drug developers to exploit this burst of innovation and consider whether other vectors — viral or non-viral — will see the same kind of progress and diversify the options.

Chair: Florencia Segal, M.D. Partner, MPM BioImpact

Panelists: Zandy Forbes, Ph.D., President & CEO MeiraGTx

Lexi Rovner, Ph.D., Co-founder & CEO, 64x Bio

Henning Stennicke, Ph.D., Chief Scientific Officer, Spur Therapeutics

2:10 PM – 2:50 PM



### **The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox?**

With more than 20 types of cell therapies derived from iPSCs in their pipelines, biotechs are on the cusp of breaking open a major new avenue for engineering cell products with a desired set of functions. This Round will ponder important questions that still remain: In the age of single-cell transcriptomics, what can be gleaned about the fidelity of reprogramming and cell durability? What is the field learning about best practices for manipulating and scaling the cells without compromising their benefits? And what bar must they beat vis a vis regenerative approaches based on protein therapeutics or traditional modalities?

Chair: Stephanie Oestreich, Ph.D., Managing Director, Myeloma Investment Fund

Panelists: Erin Kimbrel, Ph.D., President & Head of Astellas Institute for

Regenerative Medicine, Astellas Pharma

Samuel Lynch, Chairman & CEO, Lynch Regenerative Medicine, and Board Director, Vanderbilt University Medical Center

Marinna Madrid, Ph.D., Co-founder & Chief Product Officer, Cellino Biotech

Krishnendu Roy, Ph.D., Dean of Engineering and Founding Director, NSF ERC for Cell Manufacturing Technologies, Vanderbilt University

2:50 pm – 3:20 pm

Afternoon Networking Break

3:20 pm – 4:00 pm



### **Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies?**

CRISPR-Cas9 has catalyzed a world of therapeutic programs, but the fundamental limitations of gene editing still haven't been solved. Researchers have discovered new nucleases yielding base, prime and epigenetic editors that allow pinpoint changes and avoid double-stranded DNA breaks. Next-generation transposases and recombinases that facilitate large-scale genomic alterations are coming up fast. The potential for off-target edits remains, however. This Round will ask whether incremental advances in clinical-stage technologies can remove that barrier, or whether it will take a shift to newer types of biological machinery.

Chair: Deborah Palestrant, Ph.D., Partner, 5AM Ventures, Exec. Chair, 4:59 Initiative

Panelist: Andrew Bellinger, M.D., Ph.D., Advisor, Verve Therapeutics

Clare Murray, Ph.D., SVP Corporate Development & Operations, Life Edit Therapeutics

Gregory Newby, Ph.D., Assistant Professor, Johns Hopkins University

Becky Pferdehirt, Ph.D., Investment Partner, Andreessen Horowitz



4:00 pm – 4:40 pm



### **Souping up cancer cell therapies: Is the juice worth the squeeze?**

As cytotoxic cell therapies have carved out their niche, cancer researchers are churning out new strategies to improve their performance, from knocking out genes that promote exhaustion, to adding in stimulators or switches that respectively boost or limit their expansion capacity. What are the limits to the number and types of manipulations these cells can undergo? This Round will identify which CAR T cell manipulation strategies are rising above the noise, particularly for solid tumors, and ask whether other cancer-killing cell types such as TILs and NK cells can benefit as well.

**Chair:** Kristin Hege, M.D., Board Member, Adaptimmune, Mersana, Kelonia and former SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb

**Panelists:** Aaron Foster, Ph.D., Chief Scientific Officer, Outpace Bio  
Mark Frolich, M.D., CEO, Indapta Therapeutics  
Sasha Huhlov, Ph.D., Head of Search and Evaluation, Center for External Innovation, Takeda Pharmaceutical  
Carl Novina, M.D., Ph.D., Professor, Dana-Farber Cancer Institute

4:40 pm – 5:30 pm

### **Closing the innovation gap: Partnerships for next-gen treatments**

In the age of big data, causal human biology and modality expansion there is an opportunity to significantly accelerate and broaden the scope of clinical translation through innovation partnerships. In this panel, biopharma execs, VCs, and academic leaders discuss how to join forces to find the next generation of breakthrough treatments early and bring them to market within years, not decades.

**Chair:** Daniel von Bornstädt, M.D., Associate Partner, McKinsey & Company

**Panelists:** Stacy Feld, Regional Head, J&J Innovation  
Stephen Fesik, Ph.D., Orrin H. Ingram II Chair Cancer Research & Professor of Biochemistry, Pharmacology, and Chemistry, Vanderbilt University  
Sophie Kornowski, PharmD, CEO, Boston Pharmaceuticals  
Jérôme Van Biervliet, Ph.D., Managing Director, VIB

5:30 pm – 7:00 pm

### **Poster Spotlight Networking Reception: At the Forefront of Translational Innovation**

7:30 pm – 10:00 pm

### **Rounds About Town**

Build stronger connections with academics, investors, and biopharma execs by joining BioCentury's "Rounds About Town" walking tour. Visit Nashville honky-tonks, live music venues, and other cultural sites in Music City as you network with Grand Rounds attendees.

*\*Depart from Four Seasons lobby. Please note food, drinks, and other expenses must be paid for separately.*

[Click here for more information](#)

## **Wednesday, September 11, 2024**

8:00 am – 9:00 am

### **General Registration & Networking Breakfast**

8:00 am – 3:30 pm

### **C-level Partnering Meetings**



8:00 am– 8:45 am

### **Breakfast Workshop: Thinking Commercially**

You've made the discovery, secured IP, found investors and created a company. Now you must create a roadmap to commercial success. How do you build this from the get-go? How do you model for standard of care that's years away, and what's the best strategy for projecting market size and right sizing your programs? What's the best time and approach to finding partners to help move a product to market? What is your value proposition, and where does it fit within the broader context through which partners view the landscape? What are your current/future investors looking for in terms of value-inflection and an eventual exit? And how do you address needs of different stakeholders along the way? This interactive workshop brings together commercial players, investors, and dealmakers to discuss how to get your commercialization strategy right.

Chair: Joel Sandler, Ph.D., Associate Partner, Healthcare Advisory, Ipsos Healthcare Advisory

Panelist: Reagan Jarvis Ph.D., Co-Founder and CEO, Anocca AB  
Charmaine Lykins, Commercial Strategy Advisor and Former CCO, MapLight Therapeutics Inc.  
Evonne Sepsis, Managing Director, ESC Advisors  
Asish Xavier, Ph.D., VP, Venture Investments, JJDC/Johnson & Johnson Innovation

8:00 am – 3:30 pm

C-level Partnering Meetings

9:00 am – 9:45 am

### **Keynote Address: Blowing up the small molecule paradigm**

Chair: Gregory Verdine, Ph.D., Co-Founder, President & CEO, LifeMine Therapeutics, and Professor of Chemistry, Harvard University

9:45 am–10:30 am

**Fireside Chat w/ Anil Shanker, Ph.D.**, Senior Vice President for Research and Innovation, Professor of Biochemistry, Cancer Biology, Neuroscience, and Pharmacology, Meharry Medical College



## **GRAND ROUNDS III: THE HUMAN DATA REVOLUTION**

### **The human data revolution: Leveraging academic-industry symbiosis**

Academics have largely been the keepers of both the data and the methodological innovations that will advance the data revolution in biomedical science. Industry is critically dependent on applying the best tools to harness these data lakes to uncover causal disease-driving targets, predictive correlates of response and granular understanding of disease subtypes. This marriage of academic science with industry's needs could change the probability of success in discovery R&D by orders of magnitude. But the path is not simple. The Human Data Revolution Rounds will identify what must take place to make these data troves fit for purpose.

10:30 am – 10:50 am

Morning Networking Break



10:50 am – 11:30 am



### **Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity**

Data lakes are only as useful as the analytical methods that sift through them. The challenge is to mine targets and biomarkers from trillions of data points from omics biobanks and massively parallel functional screens. Long-established analytical methods now sit alongside an explosion in new techniques, including large language models. This Round will discuss which analytical methods are gaining consensus as the right tools for extracting actionable insights and look ahead to the bleeding edge methods that will define the next era.

Chair: Karen Tkach Tuzman, Ph.D., Director of Biopharma Intelligence and Head of Discovery and Preclinical Research, BioCentury

Panelists: Daniel Burkhardt, Ph.D., Head of Machine Learning Research, Cellarity  
Colin Hill, Co-founder & CEO, Aitia  
Marissa Saunders, Ph.D., Senior Director of Data Science, Recursion  
Wei-Qi Wei, M.D., Ph.D., Associate Professor, Department of Biomedical Informatics, Vanderbilt University Medical Center

11:30 am – 12:10 pm



### **Data-for-purpose: Go big, go deep, or go long?**

In an ideal world, researchers would have access to longitudinal high-resolution data on large and diverse human populations. In real life, logistical constraints usually force trade-offs. When is it best to prioritize population size, and when is the depth of data resolution per person more valuable? What questions are only solvable with longitudinal measurements? And will anonymized tokenization and data linkage make collection of these high-value datasets more routine? This Round will discuss what leading drug developers, academics and investors view as the optimal paths to making data fit for purpose.

Chair: Amy Abernethy, Ph.D., M.D., Co-founder, Highlander Health

Panelists: Gonçalo Abecasis, Ph.D., VP & Chief Genomics and Data Science Officer, Regeneron  
Caroline Chung, M.D., VP, Chief Data Officer & Assoc Prof Radiation Oncology & Radiology, MD Anderson Cancer Center  
David Goldstein, Ph.D., Co-founder & CEO, Actio Biosciences  
Mathai Mammen, M.D., Ph.D., Chairman & CEO, FogPharma  
Elizabeth Ann Stringer, Ph.D., Chief Scientific Officer, Nashville Biosciences

## **GRAND ROUNDS IV: THE DISEASE BIOLOGY BOOM**



### **While you were away: Strides in disease biology presage a translational boom**

Industry's focus on specific diseases has waxed and waned, driven by the commercial landscape. All the while, academic labs have been uncovering new disease biology and sowing the ground for leaps forward in translation. As obesity, inflammation and immunity, and neuroscience come back into favor for pharmas and investors, research labs are offering new targets, mechanisms of action, modalities and strategic approaches to propel those fields into a new age. The Disease Biology Rounds will elucidate how emerging science may make drug developers better prepared to serve these large, chronic diseases than the last time around.

Session Emcee:

Aniket Kaloti, MBBS (M.D.), Ph.D., Senior Managing Director, Healthcare M&A, Leerink Partners

12:10 am – 1:00 pm



### **Unlocking progress in neurology: How to build the case for a new target**

The call to researchers is clear: Deliver new targets and biomarkers that enable industry to reinvent how neurodegenerative and neuropsychiatric diseases are treated. Multi-omics can yield new genetic risk factors and insight into disease mechanisms that can point to new targets, but dismal preclinical models are a roadblock. This Round will explore what it will take to build a strong case for a new target in the era of human data, including where EEG-defined signatures, imaging tools such as MRI, and clinical and digital phenotyping fit into the picture.

Chair: Selina Koch, Ph.D., Executive Editor, Head of Intelligence & Research, BioCentury

Panelists: Jamil Beg, Partner, SV Health Investors  
Nancy Cox, Ph.D., Professor of Medicine, Vanderbilt University Medical Center  
Daniel Reich, M.D., Ph.D., Chief, Translational Neuroradiology Section, NINDS, NIH Attending Neuroradiologist, NIH Clinical Center  
Jill Richardson, Ph.D., Head U.K. Neuroscience, Executive Director MRL, Merck/MSD  
Adam Savitz, MD, Ph.D., Chief Medical Officer, Alto Neuroscience

1:00 pm – 2:00 pm

### **Lunchtime Plenary**

Chair: Luciana Borio, M.D., Venture Partner, Arch Ventures, ex-FDA

Panelist: Robert Carnahan, Ph.D, Professor of Pediatrics, Assoc. Dir. Vanderbilt Vaccine Center, Vanderbilt University Medical Center

2:00 pm – 2:40 pm



### **Immunity and inflammation inflection point: What determines the direction from here?**

Dramatic improvements in treating autoimmune diseases boil down to a few targets plus successful clinical and commercial strategies. What are the next targets and mechanisms that could allow drug developers to recapitulate their success in new indications and refractory patient populations? Will the early academic data on durable remissions with CD19 CAR T cells have applications in diseases with less B cell involvement? And can bispecifics offer a path to reset the immune system? This Round will probe these developments and ask whether ambition in the field has changed from managing autoimmune diseases to curing them.

Chair: Paul-Peter Tak, M.D., Ph.D., CEO, Candel Therapeutics

Panelists: Gwendolyn Binder, Ph.D., President, Science & Technology, Cabaletta Bio  
Ellen Cahir-McFarland, Ph.D., Chief Scientific Officer, Abata Therapeutics  
Aaron Esser-Kahn, Ph.D., Professor of Molecular Engineering, University of Chicago

2:40 pm – 3:30 pm

### **Closing Rapporteur Plenary: What's Next For Translational Research?**

Where does translational research go from here? This closing rapporteur session identifies the key takeaway messages from BioCentury's inaugural Grand Rounds Conference.

Panelists: Andrew Marshall, Ph.D., Venture Partner, Scion Life Sciences

Ania Payne, Ph.D., Founder, Biohub Nash

Dan Roden, M.D., Professor, SVP Personalized Medicine, Vanderbilt University Medical Center

Dan Zhang, M.D., Chairman, Hillgene

3:30 pm – 4:30 pm

### **Closing Networking Reception**

# Attending Organizations

*\*Select list of attending organizations*

2A Biosciences	Cellarity	InnoCure Therapeutics
5AM Ventures	Cellino	Ipsos
64x Bio	Changchun Genescience Pharmaceutical	J&J Innovation
Abata Therapeutics	Dana Farber Cancer Institute	Janux Therapeutics
Abion	DCVC Bio	Johns Hopkins University
Actio Biosciences	Deep Track Capital	Johnson & Johnson
Aevis Bio	Deerfield Management	KDDF
Aitia	Duet Biosystems	Keck School of Medicine of USC
Alto Neuroscience	EG427	Kelonia Therapeutics
Amazon	EpiCure Therapeutics	Korea Drug Development Fund
Andreessen Horowitz	Epiodyne	Kyowa Kirin
Anocca	ESC Advisors	LabCorp
Antion Biosciences	F2 Ventures	Lazard Freres
Arch Venture Partners	FatiAbGen	Leerink Partners
Ascensus Therapeutics	Flagship Pioneering	Life Edit Therapeutics
Astellas Institute for Regenerative Medicine	flanders.bio	Life Science Tennessee
Azcuris	FogPharma	LifeMine Therapeutics
Basking Biosciences	Genentech	Lightspeed
Biocom California	Greater Nashville Venture Capital Association (GNVCA)	LinusBio
BioCorteX	GV	Lynch Regenerative Medicine
Biogen	Hetero USA	Mahzi Therapeutics
BioInnovation Institute	Highlander Health	MapLight Therapeutics
Boston Pharmaceuticals	HSBC	McKinsey & Company
Bristol Myers Squibb	iaso Ventures	Medipost
C Cuble Lab	Indapta Therapeutics	MeiraGTx
Candel Therapeutics	Infinimmune	Milner Therapeutics Institute
		MirimGENE



# Attending Organizations

---

*\*Select list of attending organizations*

MPM BioImpact	Perceptive Advisors	Scailyte
MSD	Pi Health	Senelix
Myeloma Investment Fund	ProFound Therapeutics	Siren Biotechnology
NashBio	Radar Therapeutics	Sofinnova Partners
NINDS/NIH	Recursion	SonoThera
Novartis	Regen Innopharm	Sovargen
Novomab	Regeneron	Spur Therapeutics
Nvelop Therapeutics	Reglagene	Stand Up Therapeutics
Oak Ridge National Laboratory	RHEADC	Stanford University
Olatec Therapeutics	Safenia Therapeutics	
Outpace Bio	Samsara BioCapital	
Pappas Capital	Sana Biotechnology	

# Pre-event Networking Excursion



## The National Museum of African American Music

Join us for a visit to the National Museum of African American Music, including a delightful lunch. Get the networking started early while immersing yourself in one of the jewels of Nashville, the only museum dedicated to the history of Black music. Discover the stories behind the rhythms and melodies that have shaped genres from jazz and blues to hip-hop and R&B.

The museum's expertly-curated collections share the story of the American soundtrack by integrating history and interactive technology to bring the musical heroes of the past into the present.

*\*Limited Capacity, additional registration required.*

Email: [conferences@biocentury.com](mailto:conferences@biocentury.com) for more information

# ROUNDS ABOUT TOWN

Build stronger connections with academics, investors, and biopharma execs by joining BioCentury's "Rounds About Town" walking tour. Visit Nashville honky-tonks, live music venues, and other cultural sites in Music City as you network with Grand Rounds attendees.

\*Depart from Four Seasons lobby, Tuesday, Sept 10 at 7:30pm. Please note, food, drinks, and other expenses must be paid for separately.



**Robert's Western World**  
Nashville's Home of Traditional Country Music.

416B Broadway  
Nashville, TN 37203

11:00am - 3:00am  
0.4 miles - 8-minute walk

## Tootsie's Orchid Lounge

Famous and popular honky tonks, with 3 floors and 3 stages of live music.

422 Broadway  
Nashville, TN 37203

9:30am - 3:00am  
0.4 miles - 9-minute walk



## Skull's Rainbow Room

Circa 1948, speakeasy-style lounge offering elevated American fare, craft drinks, and nightly burlesque.

222 Printers Alley  
Nashville, TN 37219

5:00pm - 2:00am  
0.5 miles - 13-minute walk

## Bourbon Street Blues and Boogie Bar

Live music with Cajun cuisine & blues in Mardi Gras-themed surroundings.

220 Printers Alley  
Nashville, TN 37201

11:30am - 12:00am  
0.5 miles - 13-minute walk



In case you are arriving into Nashville early or staying in town after Grand Rounds 2024, here are others you may want to check out on your own



For questions or additional information, please contact:

**BRIAN DENKER**  
Director, Industry Events & Operations  
[conferences@biocentury.com](mailto:conferences@biocentury.com)



## 3rd & Lindsley Bar & Grill

Live music with performances from an eclectic roster of acts, plus food & drink.

818 3rd Ave S  
Nashville, TN 37210

6:00pm - 12:00am  
0.7 miles - 16-minute walk

*\*It is recommended that you take an Uber/Taxi to/from*



## Rudy's Jazz Room

Intimate, unique, cozy atmosphere with live jazz nightly.

809 Gleaves St  
Nashville, TN 37203

5:30 pm - 11:30 pm  
Closed on Tuesdays, BUT a must-visit if you stay before or after Grand Rounds!  
0.9 miles - 21-minute walk



## Station Inn

World's best bluegrass, classic country, Americana and roots music.

402 12th Avenue South  
Nashville, TN 37023

7:00apm - 1:00am  
1 mile - 23-minute walk

*\*It is recommended that you take an Uber/Taxi to/from*

**\*\*Cash-only establishment with a cover charge**



# Bonus Content

## Exclusive McKinsey & Company Conference Report

At Grand Rounds, McKinsey & Company continues its 10-year role as Insights Partner at BioCentury events, presenting a conference report on key challenges in the translation of scientific advances into drug development and medical practice.



McKinsey & Company keynote presentation at the 2nd East-West Biopharma Summit, Boston, MA October 2, 2023

## Join BioCentury on the Road



**11th China Healthcare Summit**  
Oct. 30 – Nov. 1, 2024  
Shanghai



**Biotech's Next Challenge:  
Delivering on the Story**  
Nov. 19, 2024  
London



**25th BioEquity Europe**  
May 12-14, 2025  
Bruges

BioCentury's two podcasts are now available to stream on your favorite podcast platform.



Visit [www.BioCentury.com](http://www.BioCentury.com) for more information.

### The BioCentury Show



### BioCentury This Week



## Partnering opens August 19, 2024

BIOCENTURY  
**BCIQ**

Your best *decisions*  
start with the right *data*



Let us help you and your  
team members prepare  
for your 1x1 meetings.



COMPREHENSIVE/  
COMPETITIVE  
PIPELINES



COMPANY  
PROFILES



FINANCING  
ROUNDS



DEAL COMPS

Receive **complimentary access** to  
**BioCentury's business intelligence  
platform**. Research **pipelines**,  
**financings**, **deals**, and **exclusive  
analysis** to help you prepare for  
meetings with potential investors and  
partners.

BCIQ combines four databases into  
**one integrated intelligence solution**.

All of the content is **linked directly to  
BioCentury's analysis**, making it easier  
for your team to place the data into  
the right context.

Want to learn more? Schedule an  
online session to use BCIQ to prepare  
for industry conferences.



Build competitive  
landscapes fast



Evaluate key financial  
metrics of deals



Analyze detailed  
company profiles



Discover emerging  
companies



Receive custom alerts  
and notifications



Save time with fully  
integrated data sets

**BCIQ.BIOCENTURY.COM**

## Event Organizer

**BIOCENTURY** For three decades BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

### The BioCentury Business Intelligence Platform

**ANALYSIS** - BioCentury's intelligence platform supports all stages of drug development with essential analysis for: R&D, Partnering, Financing & Investment and Regulatory & Market Access.

**DATA** - BioCentury's BCIQ database combines 30 years of biopharma industry analysis with curated data, aiding financing, investing, and dealmaking activities.

**CONFERENCES** - BioCentury's C-level events are where decision-makers gather to network, partner, and debate critical issues facing the biopharma industry.

**PODCASTS & WEBCASTS** - BioCentury podcasts and webcasts are perfect for the busy biopharma executive on-the-go:

- BioCentury This Week podcast: Dig into the latest biopharma trends and hot topics on this weekly podcast with BioCentury analysts. Available on Apple, Spotify, YouTube.
- The BioCentury Show podcast/webcast: Industry KOLs join BioCentury's twice-monthly podcast/webcast to discuss turning science into medicine – from R&D to financing to public policy. Available on Apple, Spotify, YouTube.

## Insights Partner

### McKinsey & Company

McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next. [www.mckinsey.com](http://www.mckinsey.com)

## Welcome Reception Co-host



Life Science Tennessee is a statewide, nonprofit member organization whose mission is to advance and grow the life science industry in Tennessee. Life Science TN, in partnership with its foundation arm BioTN, facilitates connections between private companies, research institutions, and economic development groups, advocates for

policies that support the industry at the local, state, and federal level, and manages programs that support innovation, early-stage growth, and workforce development.

Life Science TN is driven by its members that are involved in the discovery and application of life science products, including world-renowned brands and research institutions as well as startup ventures. [www.lifesciencetn.org](http://www.lifesciencetn.org)

## Founding Investors



5AM Ventures is a leading investment firm focused on funding and building next-generation life sciences companies.

[5amventures.com](http://5amventures.com)



ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease. [www.archventure.com](http://www.archventure.com)



Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care. As of December 2023, the firm manages more than \$14.6 billion in assets.

Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company. [www.deerfield.com](http://www.deerfield.com)

### F2 Ventures

F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact. [www.f2-ventures.com](http://www.f2-ventures.com)



Iaso Ventures is a venture capital firm located in Boston. Our investor-operator team and strategic partner network is passionate about helping early-stage ventures succeed and move the needle in the brain health sector. [iasoventures.com](http://iasoventures.com)





**Johnson & Johnson** At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. [njinnovation.com/venture-investing-ijdc/year-in-review](http://njinnovation.com/venture-investing-ijdc/year-in-review)

**Lightspeed** Serving bold builders of the future.

For over twenty years Lightspeed has been the first investor and an early backer of some of the most innovative companies in the world. In service of bold founders with big ideas, we stand behind our companies with high conviction from Seed to Series F and beyond. [lsvp.com](http://lsvp.com)

**MPM BioImpact** MPM BioImpact is a world-leading biotechnology investment firm with more than three decades of experience creating and investing in innovative biotechnology companies seeking to deliver transformative therapies to patients in the areas of highest unmet medical need. MPM BioImpact strives to power novel medical breakthroughs that transform patients' lives. It invests across the biotech landscape with its early-stage venture capital funds, a public equities fund, and impact funds investing in both private and public companies. [mpmbioimpact.com](http://mpmbioimpact.com)

**pappas CAPITAL** Pappas Capital is a global venture capital and commercial development firm investing in next-generation life science, agriculture, and technology companies. The firm has raised more than \$800 million and has guided the launch or development of more than 100 companies through its Pappas Ventures business unit, its Specialized Fund Management unit, and its Translational Medicine initiative. Twenty-six FDA approved products have come from Pappas Capital portfolio companies. [www.pappas-capital.com](http://www.pappas-capital.com)

**playground** Playground Global is a pioneering early-stage venture capital firm backing technical and scientific founders with hands-on engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground's mission is to transform ambitious ideas into impactful businesses that benefit humanity and the planet. We invest in areas spanning across automation, decarbonization, engineered biology and next gen compute. Playground has been an early – and frequently first investor – in companies that include d-Matrix, MosaicML (acq. by Databricks), PsiQuantum, Relativity Space, Strand Therapeutics and Ultima Genomics. [playground.vc](http://playground.vc)

**Sofinnova partners** Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. [www.sofinnovapartners.com](http://www.sofinnovapartners.com)

**SV HEALTH INVESTORS** SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. [svhealthinvestors.com](http://svhealthinvestors.com)

**SYNCONA** Syncona's purpose is to invest to extend and enhance human life. It does this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need, for the benefit of all our stakeholders. Syncona focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams.

Syncona's balance sheet underpins its strategy, enabling it to take a long-term view as the company looks to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. [www.synconaltd.com](http://www.synconaltd.com)

**THIRD ROCK VENTURES** We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients' lives. [www.thirdrockventures.com](http://www.thirdrockventures.com)

**xontogeny** Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders, and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease. We offer our experienced team and deep network of industry consultants and service providers along with seed investment capital across a variety of technologies, including therapeutics, diagnostics, and devices with the singular goal of shepherding each program through a compelling clinical proof-of-concept study. [xontogeny.com](http://xontogeny.com)

**BIOCENTURY**  
**Grand Rounds** 21

## Sponsors



In our world of rapid change, the need for reliable information to make confident decisions has never been greater.

At Ipsos we believe our clients need more than a data supplier, they need a partner who can produce accurate and relevant information and turn it into actionable truth.

This is why our passionately curious experts not only provide the most precise measurement, but shape it to provide True Understanding of Society, Markets and People.

To do this we use the best of science, technology and know-how and apply the principles of security, simplicity, speed and substance to everything we do. So that our clients can act faster, smarter and bolder.

Ultimately, success comes down to a simple truth: YOU ACT BETTER WHEN YOU ARE SURE [www.ipsos.com/en-us](http://www.ipsos.com/en-us)



Korea Drug Development Fund (KDDF) is a government agency funded by three government ministries (Ministry of Science and ICT, Ministry of

Trade, Industry and Energy, and Ministry of Health and Welfare). We aim to actively fund and provide the necessary support for drug development to academia and pharmaceutical industries.

KDDF funds and sponsors innovative drug development projects from lead to the clinical stage, encompassing academia, research institutes, biotech, and pharmaceutical companies. Besides funding drug development projects, KDDF also supports business development for out-licensing, co-development, and attracting funding from abroad. [www.kddf.org/en](http://www.kddf.org/en)



Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. [www.labcorp.com](http://www.labcorp.com)



Leerink Partners is a highly specialized healthcare investment bank with a legacy of excellence in the financial industry. The firm's experienced team delivers innovative advisory solutions, capital raising expertise, and unique insights to empower clients to achieve their strategic objectives. Since inception the firm has advised on \$60 billion, helped clients raise over \$165 billion and has established itself as a trusted partner to healthcare companies and their investors. The firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority. [www.leerink.com](http://www.leerink.com)



At NashBio, we make complex healthcare data easy to use. From idea to execution, we leverage real-world clinical, genomic and imaging data to advance the discovery and development of new therapeutics and diagnostics.

Modern healthcare systems produce endless amounts of data, but finding the right data to enhance your organization's research and development activity can be a big challenge.

Our approach focuses on your use case: tailoring a multimodal dataset to your unique specifications to achieve an optimal return on your clinical, operational and financial investment.

At NashBio, Smarter Data is in Our DNA. [nashbio.com](http://nashbio.com)



Nutter, McClennan & Fish advises biotechnology companies and investors. We provide timely, pragmatic guidance to strategic buyers looking to capitalize on market opportunities, investors seeking to expand their presence, and companies looking for experienced counsel to guide them through the complexities of a transaction. We have a proven track record of successfully protecting Intellectual property assets. We help clients unlock the value of their IP, creating revenue streams from licensing and sales. We also develop IP strategies which determine what innovations should be protected or bolstered and the ones to be licensed or abandoned for optimal return on investment. [www.nutter.com](http://www.nutter.com)



## Supporting Organizations



Biocom California is the advocate for California's life science sector. We work on behalf of 1,700+ members to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs and create value-driven purchasing programs.

Founded in 1995 in San Diego, we provide the strongest public voice to research institutions and companies that fuel the local and state-wide economy and help our members produce novel solutions that improve the human condition. In addition to our headquarters, we operate core offices in LA and the Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. [www.biocom.org](http://www.biocom.org)



BII offers entrepreneurially-minded researchers or anyone with a research-based idea help to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts. Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe. [bii.dk](http://bii.dk)



flanders.bio is a dynamic, independent and member driven life sciences cluster organization with currently more than 350 members and partners from Flanders, Belgium and abroad. We enable our members and partners to create value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. Since 2004, flanders.bio and its members are the proud advocates of a reputable global-impact ecosystem in biotech and life sciences. [flanders.bio/en](http://flanders.bio/en)



Georgia Bio (GaBio) is the state's most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For over 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.

GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. [www.gabio.org](http://www.gabio.org)



The Greater Nashville Venture Capital Association (GNVCA) is a membership organization comprised of investors from pre-seed to growth equity (venture capital, angel investors, private offices, and corporate venture partners) in the greater Nashville region, working to make Middle Tennessee a premier area to launch, grow, and invest in companies.

The purpose of the GNVCA is to increase the availability of capital and talent that is available to venture capital and angel investors in the region, so that our most innovative entrepreneurs can build successful companies that create jobs and economic growth for the region. [gnvca.org](http://gnvca.org)

Life Science Tennessee is a statewide, nonprofit member organization whose mission is to advance and grow the life science industry in Tennessee. Life Science TN, in partnership with its foundation arm BioTN, facilitates connections between private companies, research institutions, and economic development groups, advocates for policies that support the industry at the local, state, and federal level, and manages programs that support innovation, early-stage growth, and workforce development.

Life Science TN is driven by its members that are involved in the discovery and application of life science products, including world-renowned brands and research institutions as well as startup ventures. [www.lifesciencetn.org](http://www.lifesciencetn.org)



The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme, which aims to transform pioneering science into therapies. It was founded in 2015 as a new paradigm for an academic Institution, based on bridging the gap between academia and Industry. The research institute opened in summer 2019 in the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for these cross-sector collaborations. We have also built a global research community of 80 affiliated organisations.



The Institute was co-founded by Tony Kouzarides and Jonathan Milner. The therapeutics concept and mission was developed following the establishment of the Milner Therapeutics Consortium by Tony Kouzarides. Jonathan Milner is a benefactor to the building of the Research Institute, which bears his name. Tony and Jonathan are also co-founders of Abcam plc, an antibody reagents provider based in Cambridge. [www.milner.cam.ac.uk](http://www.milner.cam.ac.uk)



The SPARK model is a cost-effective way to facilitate development of research discoveries into novel therapeutics or diagnostics. More than 40 academic institutions around the world have successfully developed their own SPARK programs. SPARK at Stanford actively supports our US and international partners in the development of their programs with visits, guest lectures, and more. [sparkglobal.io](http://sparkglobal.io)



Women In Bio is an organization of professionals committed to promoting careers, leadership, and entrepreneurship for all women in the life sciences.

We are an organization of professional women from all career walks in the field of life sciences. We are all volunteers and we all share the goal of enabling and empowering women to reach the highest levels of leadership, and — more importantly — to fulfill their own career aspirations.

Our members reflect the increasing spread of the life sciences. We belong to biotech and pharma companies, universities and institutes, law and accounting firms, marketing and PR firms, CROs, and CMOs. Many of our members are entrepreneurs, and a focus on entrepreneurship has remained core to WIB's mission. [www.womeninbio.org](http://www.womeninbio.org)



# Register Online

[www.BioCenturyGrandRounds.com](http://www.BioCenturyGrandRounds.com)

Registration Type	Early Bird Ends June 3, 2024	Advanced Ends August 2, 2024	Standard
Industry Pass (Non-Academic / Non-Service Provider)	\$1495	\$1695	\$1895
Academic Pass (Full-time affiliation with an educational or research institution)	\$995	\$1195	\$1395
Academic Pass + Poster Presentation* (Full-time affiliation with an educational or academic institution + poster presentation)	\$1095	\$1295	\$1495
Presenting Company Presentation Package* (Includes two passes)	\$2495	\$2795	\$3095
Presenting Company Presentation Package + Poster Presentation* (Includes two passes)	\$2695	\$2995	\$3295
Service Provider Pass (CRO, CMO, Economic Development Organizations, Law Firms, Communications/IR Firms, Consultants, Executive Recruiters, Merchants, and other service providers.).	\$1870	\$2120	\$2370

*\*Email: [grandroundshelp@biocentury.com](mailto:grandroundshelp@biocentury.com) for additional information on how to register.*

### Group discounts:

Discounts are available for groups of four (4) or more from any one company. For additional information and pricing, please email: [grandroundshelp@biocentury.com](mailto:grandroundshelp@biocentury.com).



Grand Rounds 2024 will take place at:  
**Four Seasons Hotel Nashville**  
100 Demonbreun St  
Nashville, TN 37201  
Telephone: +1 (615) 610-6995

For details on hotel and travel arrangements, please refer to our [hotel and travel page](#) to book accommodations.

